Tumor immunity via homeostatic T cell proliferation: Mechanistic aspects and clinical perspectives

Springer Seminars in Immunopathology

Volumn 27, Issue 1, 2005, Pages 75-85

  Baccala, Roberto ^a   Gonzalez Quintial, Rosana ^a   Dummer, Wolfgang ^b   Theofilopoulos, Argyrios N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GENENTECH INC   (United States)

Author keywords

Anti tumor autoimmunity; Cancer immunotherapy; Lymphopenia; Melanoma; Tumor antigens

Indexed keywords

AUTOANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN RECOGNITION; AUTOIMMUNITY; AUTOTRANSPLANTATION; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL FUNCTION; CELL SPECIFICITY; CELLULAR IMMUNITY; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MODEL;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; HOMEOSTASIS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 21344438431     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00281-004-0196-9     Document Type: Review

References (85)

1. Ahlers JD, Belyakov IM, Terabe M, et al (2002) A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci USA 99:13020
2. Antonia SJ, Seigne J, Diaz J, et al (2002) Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167:1995
3. Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99:931
4. Baccala R, Theofilopoulos AN (2005) The new paradigm of T-cell homeostatic proliferation-induced autoimmunity. Trends Immunol 25:5
5. Becker TC, Wherry EJ, Boone D, et al (2002) Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195:1541
6. Berzofsky JA, Ahlers JD, Belyakov IM (2001) Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1:209
7. Berzofsky JA, Terabe M, Oh S, et al (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515
8. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305:200
9. Boon T, Old LJ (1997) Cancer tumor antigens. Curr Opin Immunol 9:681
10. Borrello I, Sotomayor EM, Rattis FM, et al (2000) Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95:3011
11. Brocker T (1997) Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J Exp Med 186:1223
12. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1
13. Cho BK, Rao VP, Ge Q, et al (2000) Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 192:549
14. + T cells in the absence of self peptide:MHC complexes. J Immunol 165:2458
15. Dranoff G, Jaffee E, Lazenby A, et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539
16. Dudley ME, Wunderlich JR, Robbins PF, et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850
17. Dummer W, Niethammer AG, Baccala R, et al (2002) T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 110:185
18. Dunn GP, Bruce AT, Ikeda H, et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991
19. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611
20. Ernst B, Lee DS, Chang JM, et al (1999) The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 11:173
21. Fong L, Hou Y, Rivas A, et al (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98:8809
22. + T cells. Immunology 107:5
23. Ge Q, Rao VP, Cho BK, et al (2001) Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/ MHC epitopes and strength of their interaction with T cell receptors. Proc Natl Acad Sci USA 98:1728
24. Gilboa E (2001) The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2:789
25. Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251
26. + T cells in lymphopenic hosts. Immunity 11:183
27. Goldrath AW, Bogatzki LY, Bevan MJ (2000) Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 192:557
28. + T cells. J Exp Med 195:1515
29. + T cells? J Exp Med 198:1089
30. Gunzer M, Janich S, Varga G, et al (2001) Dendritic cells and tumor immunity. Semin Immunol 13:291
31. Hellstrom KE, Hellstrom I, Kant JA, et al (1978) Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med 148:799
32. Houghton AN, Gold JS, Blachere NE (2001) Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 13:134
33. Hu HM, Poehlein CH, Urba WJ, et al (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62:3914
34. Jaffee EM, Hruban RH, Biedrzycki B, et al (2001) Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19:145
35. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999
36. Kieper WC, Jameson SC (1999) Homeostatic expansion and phenotypic conversion of naive T cells in response to self peptide/MHC ligands. Proc Natl Acad Sci USA 96:13306
37. + T cells. J Exp Med 195:1533
38. King C, Ilic A, Koelsch K, et al (2004) Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117:265
39. Kirberg J, Berns A, Boehmer H von (1997) Peripheral T cell survival requires continual ligation of the T cell receptor to major histocompatibility complex-encoded molecules. J Exp Med 186:1269
40. Kirk CJ, Mule JJ (2000) Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 11:797
41. Klinman DM, Yi AK, Beaucage SL, et al (1996) CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93:2879
42. Kondrack RM, Harbertson J, Tan JT, et al (2003) Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med 198:1797
43. + memory T cells by opposing cytokines. Science 288:675
44. Kwak LW (1998) Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Ann Oncol 9 Suppl 1:S41
45. + T cells and homeostatic T cell proliferation in Y-chromosome-associated murine lupus. J Immunol 167:2354
46. + T cell memory. Proc Natl Acad Sci USA 101:9357
47. Mackall CL, Bare CV, Granger LA, et al (1996) Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 156:4609
48. Maine GN, Mule JJ (2002) Making room for T cells. J Clin Invest 110:157
49. Maio M, Fonsatti E, Lamaj E, et al (2002) Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 51:9
50. Moses CT, Thorstenson KM, Jameson SC, et al (2003) Competition for self ligands restrains homeostatic proliferation of naive CD4 T cells. Proc Natl Acad Sci USA 100:1185
51. Murali-Krishna K, Ahmed R (2000) Cutting edge: Naive T cells masquerading as memory cells. J Immunol 165:1733
52. Murali-Krishna K, Lau LL, Sambhara S, et al (1999) Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 286:1377
53. Nanda NK, Sercarz EE (1995) Induction of anti-self-immunity to cure cancer. Cell 82:13
54. Nestle FO, Banchereau J, Hart D (2001) Dendritic cells: On the move from bench to bedside. Nat Med 7:761
55. North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressorT cells. J Exp Med 155:1063
56. Oehen S, Brduscha-Riem K (1999) Naive cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: a pitfall for T cell memory studies? Eur J Immunol 29:608
57. Overwijk WW, Restifo NP (2000) Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol 20:433
58. Pardoll DM (1999) Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96:5340
59. Phan GQ, Yang JC, Sherry RM, et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372
60. Polic B, Kunkel D, Scheffold A, et al (2001) How alpha beta T cells deal with induced TCR alpha ablation. Proc Natl Acad Sci USA 98:8744
61. + T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 59:301
62. Rooke R, Waltzinger C, Benoist C, et al (1997) Targeted complementation of MHC class II deficiency by intrathymic delivery of recombinant adenoviruses. Immunity 7:123
63. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380
64. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909
65. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
66. Salgia R, Lynch T, Skarin A, et al (2003) Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21:624
67. Schluns KS, Kieper WC, Jameson SC, et al (2000) Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 1:426
68. Seddon B, Tomlinson P, Zamoyska R (2003) Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol 4:680
69. Seddon B, Zamoyska R (2002) TCR and IL-7 receptor signals can operate independently or synergize to promote lymphopenia-induced expansion of naive T cells. J Immunol 169:3752
70. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211
71. Simons JW, Mikhak B, Chang JF, et al (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160
72. Soiffer R, Lynch T, Mihm M, et al (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95:13141
73. Sutmuller RP, Duivenvoorde LM van, Elsas A van, et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823
74. Swain SL, Hu H, Huston G (1999) Class II-independent generation of CD4 memory T cells from effectors. Science 286:1381
75. Tan JT, Dudl E, LeRoy E, et al (2001) IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA 98:8732
76. + cells. J Exp Med 195:1523
77. Tanchot C, Lemonnier FA, Perarnau B, et al (1997) Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 276:2057
78. Terando A, Mule JJ (2003) On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother 52:680
79. Theofilopoulos AN, Dummer W, Kono DH (2001) T cell homeostasis and systemic autoimmunity. J Clin Invest 108:335
80. Troy AE, Shen H (2003) Cutting edge: Homeostatic proliferation of peripheral T lymphocytes is regulated by clonal competition. J Immunol 170:672
81. Viret C, Wong FS, Janeway CA Jr (1999) Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition. Immunity 10:559
82. Vivien L, Benoist C, Mathis D (2001) T lymphocytes need IL-7 but not IL-4 or IL-6 to survive in vivo. Int Immunol 13:763
83. Witherden D, Oers N van, Waltzinger C, et al (2000) Tetracycline- controllable selection of CD4(+) T cells: half-life and survival signals in the absence of major histocompatibility complex class II molecules. J Exp Med 191:355
84. Zaremba S, Barzaga E, Zhu M, et al (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570
85. + T cells in vivo by IL-15. Immunity 8:591